Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma

Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma: An Immunohistochemical Study.

Vitamin D has a crucial role in cancer control and prevention.vitamin D receptor (VDR) and its heterodimer Retinoid X receptor (RXR) are equally important in the cell. This ligand (vitamin D) and receptors (VDR-RXR) complex together triggers downstream DNA damage response in the cell.

Retinoid receptors are a superfamily of nuclear receptors. The preferred receptor that attaches to VDR is RXR, with its subunits α, β and γ. RXR α is more frequent in the skin than other tissues, while β occurs in internal organs and γ is frequently related to neural disorders.

the investigator hopes to assess prognosis of SCC & BCC by using RXR-α biomarker & attempts to use it in the treatment.

Study Overview

• Status: Not yet recruiting
• Conditions: Non-melanoma Skin Cancer

• Study Type: Observational
• Enrollment (Anticipated): 50

Contacts and Locations

• Study Contact: Name: Fatma M.Hamdan; Phone Number: 01000419587; Email: fatma.mohammad@med.sohag.edu.eg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Blocks obtained from cutaneous basal and squamous cell carcinoma tissue from 50 patients.

Description

Inclusion Criteria:

1. Squamous cell carcinoma and basal cell carcinoma.
2. Incisional & excisional biopsies.
3. All the studied cases include sufficient materials for the immunohistochemical study 4. Complete clinical data

Exclusion Criteria:

1. Patients with a history of preoperative chemotherapy and/or radiotherapy.
2. Insufficient or tiny tissue biopsies.

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma	immuohistochemical expression of RXR-α in Squamous and Basal Cell Carcinoma	One or two days after staining sections with the marker.

Collaborators and Investigators

• Sponsor: Sohag University

Study record dates

Study Major Dates

• Study Start (Anticipated): December 1, 2022
• Primary Completion (Anticipated): September 1, 2023
• Study Completion (Anticipated): December 1, 2023

Study Registration Dates

• First Submitted: September 20, 2022
• First Submitted That Met QC Criteria: September 20, 2022
• First Posted (Actual): September 22, 2022

Study Record Updates

• Last Update Posted (Actual): September 22, 2022
• Last Update Submitted That Met QC Criteria: September 20, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms, Basal Cell; Carcinoma, Basal Cell
• Other Study ID Numbers: Soh-Med-22-09-05

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No